Trial Profile

A Phase III Randomized, Open-Labeled Clinical Trial of MK3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-Sided Infective Endocarditis Caused by MRSA.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daptomycin (Primary) ; Vancomycin
Indications Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections; Septicaemia; Skin and soft tissue infections
Focus Registrational; Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

27 Sep 2011 Treatment table and purpose added.
20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
07 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com